Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity

Research output: Contribution to journalArticle

Standard

Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity. / Tryding, Nils; Sterner, Gunnar; Berg, Bertel; Harris, Alan; Lundin, S.

In: Nephron, Vol. 45, No. 1, 1987, p. 27-30.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity

AU - Tryding, Nils

AU - Sterner, Gunnar

AU - Berg, Bertel

AU - Harris, Alan

AU - Lundin, S

PY - 1987

Y1 - 1987

N2 - Maximum urine concentration capacity was studied in healthy adults using different routes and doses of administration of 1-deamino-8-d-arginine vasopressin (DDAVP) - desmopressin. Plasma levels of DDAVP showed a dose-dependent increase after the subcutaneous but not after the intranasal administration. The effect on urine osmolality was similar but more prolonged after the subcutaneous as compared to the intranasal route. We conclude that subcutaneous injection is a simple and reliable way of administering DDAVP. A dose of 4 μg in adults is optimum diagnostically and it corresponds to 20-40 μg administered intranasally.

AB - Maximum urine concentration capacity was studied in healthy adults using different routes and doses of administration of 1-deamino-8-d-arginine vasopressin (DDAVP) - desmopressin. Plasma levels of DDAVP showed a dose-dependent increase after the subcutaneous but not after the intranasal administration. The effect on urine osmolality was similar but more prolonged after the subcutaneous as compared to the intranasal route. We conclude that subcutaneous injection is a simple and reliable way of administering DDAVP. A dose of 4 μg in adults is optimum diagnostically and it corresponds to 20-40 μg administered intranasally.

U2 - 10.1159/000184066

DO - 10.1159/000184066

M3 - Article

VL - 45

SP - 27

EP - 30

JO - Nephron - Clinical Practice

JF - Nephron - Clinical Practice

SN - 0028-2766

IS - 1

ER -